A nine-year-old has become the first patient in a newly eligible age group to receive a disease-modifying diabetes treatment at Lurie Children's Hospital in Chicago, part of what the hospital calls the first therapy of its kind approved for children and adolescents newly diagnosed with type 1 diabetes. The drug, Tzield, works by targeting the immune processes that attack insulin-producing cells, rather than simply managing blood sugar after the fact.
Lurie Children's identifies the child as Karsyn, while a snippet from FOX 32 Chicago names the first eligible patient as Carson; the two accounts differ on the child's name. Lurie Children's describes the treatment as designed to slow the progression of type 1 diabetes by targeting the immune processes that damage insulin-producing cells, with the goal of helping preserve whatever insulin production remains at diagnosis.
Who Qualifies and How the Treatment Works
Under the expanded approval described by the hospital, Tzield is available to patients ages 8 to 17 who were diagnosed with stage 3 type 1 diabetes within the previous eight weeks and who still show evidence of remaining insulin production. For this newly diagnosed group, treatment involves two 12-day outpatient intravenous infusion courses spaced six months apart, with each individual session lasting roughly one to two hours.
Lurie Children's administers the infusions at its main campus in Streeterville as well as at Central DuPage Hospital, and the hospital says it treats more than 200 newly diagnosed type 1 diabetes patients every year — a population that now has access to an option beyond standard insulin management.
A Different Approval Track for Younger Kids
Tzield's reach has also been expanding on a separate track. According to Beyond Type 1, the FDA separately expanded eligibility for the drug in stage 2 type 1 diabetes patients from age 8 and up down to children as young as 1 year old — a distinct indication from the stage 3, newly diagnosed use Lurie Children's is now offering, with its own separate criteria.
The underlying approval for the stage 3 use in recently diagnosed pediatric patients traces back to a June 2026 announcement from the U.S. Food and Drug Administration, which said the therapy was approved to delay the decline of insulin production in pediatric patients ages 8 through 17 recently diagnosed with the disease. That approval built on research published in the New England Journal of Medicine, where a phase 3 randomized, placebo-controlled trial tracked beta-cell function in children and adolescents given the same two-course, 12-day infusion regimen, with researchers measuring changes in insulin production at 78 weeks.
Similar Rollouts Beyond Chicago
Lurie Children's is not the only hospital system navigating this shift. Across the Atlantic, the BBC reported that a patient named Annette Quilter received the first NHS dose of teplizumab at Queen Elizabeth Hospital Birmingham, after the drug became available through Britain's National Health Service in June 2026 for eligible children over eight and adults with stage 2 type 1 diabetes.
Closer to home, endocrinologists at Children's Hospital Los Angeles have been discussing how disease-modifying therapies like this one are reshaping pediatric type 1 diabetes screening, family counseling, and treatment decisions, according to the hospital's own account. For families at Lurie Children's facing a fresh diagnosis, the hospital says the new option is meant to offer hope at a moment that can otherwise feel overwhelming.
